Exclusive-Medicaid Fuels US Coverage of Novo, Lilly Weight-Loss Drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...